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DE BOER, S. F., J. VAN DER GUGTEN AND J. L. SLANGEN. Effects of chlordiazepoxide, flumazenil and DMCM on plasma 
catecholamine and corticosterone concentrations i  rats. PHARMACOL BIOCHEM BEHAV 38(1) 13-19, 1991.--The ffects of 
drugs representing three classes of benzodiazepine (BDZ) receptor-acting a ents on circulating corticosterone (CS), noradrenaline 
(NA) and adrenaline (A) were examined in unstressed rats. Intragastfic administration f a single-dose of the inverse agonist 3-car- 
bomethoxy-4-ethyl-6,7-dimethoxy-13-carboline (DMCM; 10 mg/kg) evoked 15-, 4- and 1.5-fold increases in plasma CS, A and NA, 
respectively, as compared to control values. The DMCM-induced CS, A and NA rises were completely blocked by combined treat- 
ment with the BDZ antagonist flumazenil (Ro 15-1788; 20 mg/kg). Flumazenil given alone did not affect plasma hormone levels. 
Administration (either intragastrically or intraperitoneally) of a single-dose of the BDZ agonist chlordiazepoxide (CDP; 20 mg/kg) 
produced a 10- to 15-fold increase in plasma CS but caused no change in plasma NA and A contents. Pretreatment with flumazenil 
blocked the CDP-elieited release of CS. The findings indicate that the CNS mechanisms controlling pitnitary-adrenocortieal and 
sympatho-adrenal outflow under basal conditions are functionally inked to central-type BDZ receptor system(s). Drugs with agonist 
or inverse-agonist actions at these receptor sites can be differentiated from each other by their distinct effects on plasma NA and A, 
but not CS, release. 
Noradrenaline Adrenaline Corticosterone Chlordiazepoxide Flumazenil DMCM BDZ receptor ligands 
Rat 
STRESSFUL or anxiety-provoking environmental events gener- 
ally activate the pituitary-adrenocortical axisand the sympathet- 
ic-adrenomedullary system resulting in elevated blood plasma 
concentrations of the glucocorticoid corticosterone (CS) and of 
the catecholamines (CAs) noradrenaline (NA) and adrenaline (A) 
(1,7). In experimental nimals as well as in man, these neuroen- 
docrine stress responses can be mimicked by administration of
benzodiazepine (BDZ) receptor ligands with so-called inverse ag- 
onist (i.e., anxiogenic) intrinsic activity such as the 13-carbolines 
DMCM, FG 7142 or [3-CCE (6, 15, 25, 26, 29). In accordance 
with the anxiogenic properties of these compounds i their ability 
to enhance the stress-elicited increases in CS release (26). 
On the other hand, numerous reports have demonstrated that 
BDZ receptor ligands with agonist (i.e., anxiolytic) intrinsic ac- 
tions like the benzodiazepines chiordiazepoxide (CDP) or diaz- 
epam, can prevent or oppose the stress-induced activation of 
pituitary-adrenocortical (10, 11, 16-20, 22, 27, 29, 31) and sym- 
pathetic-adrenomedullary systems (4,34). In addition to anxiolytic 
and anxiogenic BDZ-ligands, a third class of substances (i.e., the 
BDZ-receptor antagonists) appears to exert little intrinsic effect 
itself at the central BDZ-receptor, but is able to effectively antag- 
1These investigations were supported inpart by the Foundation for Medical 
onize the pharmacological effects of both the agonists and the in- 
verse agonists. Indeed, the prototypical BDZ receptor antagonist, 
flumazenil (Ro 15-1788), was shown to block the stress-like l- 
evations in plasma CS, NA and A concentrations induced by the 
inverse agonist ~-CCE (25) and to prevent he inhibition of 
stress-elevated CS contents by the BDZ agonist diazepam (2,8). 
Based on these findings, it has been proposed that BDZ-agonists 
with anxiolytic or antistress activity are well characterized by their 
potency to inhibit stress-induced levations in plasma CS and/or 
CA concentrations, while the ability to enhance these hormone 
levels in unstressed rats is a reflection of anxiogenic or stress-in- 
ducing properties typical of BDZ-inverse agonists (13, 19, 29). 
Logically, it would be expected that BDZs and other agents 
possessing anxiolytic activity would only reduce the activity in 
stress-activated neuroendocrine systems and not elevate the lev- 
els of stress hormones under basal conditions. However, this ap- 
pears not to be the case since anxiolytic doses of BDZs also elevate 
(dose-dependently) CS concentrations when administered acutely 
to unstressed rats (16, 20, 22, 27, 31). These anxiogenic or pro- 
stress effects are generally believed to arise from the sedative/ 
ataxic actions of BDZs (22, 27, 31), although such a relationship 
and Health Research MEDIGON (grant No. 900-548-087). 
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has been questioned (11). Hence, it seems that the enhancement 
of plasma CS levels in unstressed rats is not clearly related to a 
specific action at the BDZ receptor since it is produced by ago- 
nists as well as by inverse agonists of this receptor. However, it 
has not been established yet whether this effect of BDZ agonists, 
like that of the inverse agonists (25), is mediated by central BDZ 
receptors. Futhermore, it is not known whether agonists of the 
BDZ receptor also have the inverse agonist-like property to cause 
an increase in basal plasma NA and/or A concentrations. 
Therefore, the first aim of the present study was to assess the 
effects of a prototypical representative of the three different groups 
of BDZ receptor ligands, i.e., the agonist chlordiazepoxide, the 
antagonist flumazenil and the inverse-agonist DMCM, on plasma 
CS and CA concentrations in unstressed rats. The second goal 
was to determine whether the actions of CDP and DMCM can be 
blocked by pretreatment with flumazenil, in order to establish if 
the effects of these drugs are mediated through central BDZ-re- 
ceptors. Finally, in order to minimize the nondrug-related stress 
associated with common methods of drug administration (e.g., 
handling, IP or SC injection, orogastric intubation), an intragas- 
tric cannulation method was employed and validated in this study. 
METHOD 
Animals and Housing 
Male Wistar ats (Harlan-CPB, Zeist, The Netherlands) weigh- 
ing 250-275 g on their arrival in the laboratory were used as 
subjects. They were housed individually in clear Plexiglas cages 
(25 x 25 × 30 cm) on a layer of woodshavings. For at least two 
weeks prior to surgery, cages were placed in a room under con- 
ditions of constant temperature (21 -2°C) and a fixed 12-h light/ 
dark photoperiod (lights on at 07:00 a.m.). Subjects were in full 
view, sound and smell of each other, had free access to food and 
water at all times and were handled aily for weighing purposes. 
Surgery and Blood Sampling 
Under Hypnorm anesthesia (10 mg/kg fluanisone and 0.2 mg/ 
kg fentanyl) and premedicated with atropine (1 mg/kg) and diaz- 
epam (5 mg/kg), animals were provided with a silastic cannula 
(i.d. 0.5 mm; o.d. 0.9 mm; Dow Coming, USA) into the en- 
trance of the right atrium via an external jugular venotomy ac- 
cording to the techniques basically described by Steffens (28). 
This cannula allows frequent withdrawal of small amounts of 
blood without disturbing the animal either behaviorally or physi- 
ologically (28,35). Animals were also provided with a silicon 
cannula (i.d. 0.8 ram; o.d. 1.4 mm) into the antrum wall of the 
stomach. The outer ends of the cannulae were extended subcuta- 
neously to emerge at the top of the head and anchored to the skull 
(30). This indwelling catheter allows intragastric drug administra- 
tion in the freely behaving and undisturbed rat. After surgery, the 
rats were allowed to recover for at least one week before the start 
of the experiments. During this period, animals were accustomed 
to the blood sampling procedure. 
At least ninety minutes before the start of an experiment, the 
indwelling cannulae were extended by polyethylene tubes (length 
0.5 m; o.d. 1.45 ram; i.d. 0.75 mm) allowing blood sampling 
and intragastric drug infusion. Blood samples of 0.35 ml for the 
determination f NA, A and CS concentrations were taken at t = 
0, 15, 30, 60, 120 and 180 min. Immediately after each blood 
sampling an equal volume of heparinized (12.5 IU/ml) blood, 
freshly obtained from a cannulated onor rat, was transfused 
through the catheter. At the end of the experiment, the indwell- 
ing part of the heart cannula was filled with 0.9% (wt./vol) NaC1 
containing 500 IU heparin/ml plus 60% polyvinylpyrrolidone 
(Merck, Darmstadt, FRG). The indwelling part of the stomach 
catheter was filled with 0.9% saline. 
Drugs 
Chlordiazepoxide hydrochloride (Hoffmann-La Roche, Basel, 
Switzerland) was dissolved in physiological (0.9%) saline. The 
vehicle consisted of an acidified (HC1) saline solution with a sim- 
ilar acidity as the respective CDP solution (pH 3.1). In contrast 
to the acidified saline solution, the CDP solution also has a con- 
siderable buffering capacity. Therefore, cwo additional vehicles 
consisting of 0.1 M sodium-citrate/HC1 buffer with a pH of 3.0 
and 5.0, respectively, that had an approximately similar buffer- 
ing capacity as the CDP solution, were used in Experiment 1. 
Flumazenil (Ro 15-1788; Hoffmann-La Roche, Basel, Switzer- 
land) was suspended in a vehicle consisting of distilled water to 
which Tween 80 (2 drops/10 ml) was added. DMCM (methyl- 
6,7-dimethoxy-4- ethylbeta-carboline- 3-carboxylate; Schering, Ber- 
lin, FRG) was dissolved in an acidified (HC1) saline solution. All 
solutions were freshly prepared before every test. In case of in- 
traperitoneal (IP) injections, drug and vehicles were administered 
in a volume of 1 ml/kg. In case of intragastric administration a 
volume of 2 ml/kg was used. 
Experimental Procedures 
All experiments were performed in the light period between 
09:00 and 13:00. 
Experiment 1: Comparison of the Effects of lntraperitoneal 
and Intragastric CDP Administration on Plasma 
CS and CA Content 
Nine groups of 6 animals each were used in this experiment. 
Rats in the CONTROL group did not receive any drug or vehicle 
treatment and were left undisturbed in their home cages during 
the whole 120-rain sampling period. Rats in the HANDLING 
condition were gently picked up from their home cages immedi- 
ately after taking the first, baseline, blood sample at t = 0 min, 
held ('4-5 s) in the hand as if an IP injection was given and then 
returned to their home cages. Subjects in the IP-treatment groups 
were injected intraperitoneally with either acidified SALINE, buffer 
pH = 3, buffer pH = 5 or 20 mg/kg CDP. Subjects in the intragas- 
tric-treatment groups were not handled but immediately after tak- 
ing the first blood sample, CDP (20 mg/kg) or vehicle (acidified 
SALINE and buffer pH = 3) solutions were slowly (10 s) infused 
via the intragastric cannula. Blood samples were taken according 
to the time schedule described above and indicated in the figures. 
Experiment 2: Effects of CDP, DMCM and Flumazenil on 
Plasma CA and CS Concentrations 
Twenty-three rats were randomly assigned to one of three con- 
ditions. All rats received two treatments using a balanced repeat- 
ed-measures within-subject design with an intertest interval of one 
week. Each treatment consisted of two subsequent intragastfic 
infusions. One group (n = 6) received vehicle/saline and flumaze- 
nil/saline treatment. The second group (n =6) received vehicle/ 
CDP and flumazenil/CDP, whereas rats in the third group (n = 
11) received the treatments vehicle/DMCM and flumazenil/ 
DMCM. Flumazenil and CDP were administered in a dosage of 
20 mg/kg (66.0 and 59.5 txmol/kg, respectively); DMCM was 
administered in a dosage of 10 mg/kg (30.8 Ixmol/kg). Drug and 
vehicle solutions were infused via the intragastric cannula. Blood 
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samples were taken at the times indicated in the figures. 
Chemical Determinations 
Blood samples were immediately transferred to ice-cooled 
centrifuge tubes containing 10 i~l heparin solution (500 IU/ml). 
For the determination f plasma catecholamine contents, an ali- 
quot of 250 p,1 transferred blood was rapidly pipetted into chilled 
tubes containing 10 Ixl of a solution of 25 mg/ml disodium EDTA 
and 27.5 mg/ml reduced gluthatione in order to prevent CA deg- 
radation. The remaining 100 p,! blood was used for the CS assays 
and for the BDZ-receptor binding assays. After centrifugation 
(4000 × g for 10 min at 4°C), supernatants were removed and 
stored at -30°C until assayed. 
The concentrations of NA and A were measured in duplicate 
in 20 p.1 perchloric acid-deproteinized plasma ccording to a ra- 
dioenzymatic COMT-procedure (33). In short, the CAs were con- 
verted into their [3H]-methoxy derivatives by incubation with S- 
adenosyl-L-[methyl-3H]methionine (80 Ci/mmol; NEN Chemicals) 
in the presence of catechol-O-methyltransferase. Labeled prod- 
ucts were isolated by organic extraction and paper chromatogra- 
phy. After elution of the labeled products, activity was counted 
in a liquid scintillation analyzer (Philips, The Netherlands). CA 
concentrations were calculated from net DPM values for samples 
and internal standards and expressed as pg/ml. The intra- and in- 
terassay variabilities were less than 10% and 15%, respectively. 
The sensitivity of the assay was 1 pg for both NA and A. 
Plasma CS concentrations were determined in duplicate ac- 
cording to a competitive protein-binding method (24). Corticoste- 
rone was extracted with dichloromethane from 25 ixl samples of 
plasma nd the dry residue was incubated with a corticosteroid- 
binding globulin tracer solution {0.1% plasma from adrenalecto- 
mized female rats containing [1,2-3H]-corticosterone (40-50 Ci/ 
mmol; NEN Chemicals) as tracer}. Unbound steroid was removed 
using dextran-coated charcoal. Standard CS was supplied by Sigma. 
The intra- and interassay coefficients of variation were less than 
10%. Fifty percent displacement of tracer steroid was obtained at 
a concentration f 20---2 txg/dl. 
Benzodiazepine activity in plasma was measured according to 
a radioreceptor procedure (14), modified with respect o radioli- 
gand and receptor preparation (23) and adapted to small plasma 
samples. BDZ ligands were extracted from 50 p,1 samples in 175 
Ixl ethylacetate. Flumazenil containing plasma was diluted 20 
times before extractions. Extract fractions were evaporated and 
incubated with 900 V,1 bovine frontal cortex homogenate and 25 
nCi [methyl-3H]flunitrazepam (60 Ci/nmol; NEN Chemicals) at 
4°C for 60 rain. Unbound benzodiazepine was removed by rapid 
filtration through Whatman GF-B filters. CDP standards were 
used to calculate CDP equivalent levels in plasma. Plasma CDP 
equivalent concentrations of 41.5 nmol/ml (for CDP and DMCM) 
or 830 nmol/ml (for flumazenil) resulted in 50% inhibition of 
specific radioligand binding. 
Statistical Analyses 
The response-time patterns of the plasma constituents in Ex- 
periment 1 were evaluated by use of two-way analyses of vari- 
ance (ANOVA) with drug/vehicle-treatment as between-subject 
factor and sampling time as repeated-measures within-subject fac- 
tor. The profiles of hormonal changes in Experiment 2 were an- 
alyzed using a three-way ANOVA with experimental group as 
between-subject factor (3 levels), treatment aswithin-subject fac- 
tor one (2 levels) and sampling time as repeated measures with- 
in-subject factor two (6 levels). The multivariate model was used 
for the repeated-measures factor (5). Further analyses were made 
by paired Student t-tests (within-group comparisons) or by Dun- 
can's new multiple range test (between-group comparisons) to 
determine the source of the detected significance in the ANO- 
VA's (3). The criterion of significance was set at p<0.05. 
RESULTS 
Experiment 1
As shown in Fig. 1, the levels of plasma CS in uninjected and 
undisturbed control rats were low (0.8-2.3 i.tg/dl) and were found 
not to vary significantly at any time point, indicating that the 
method of blood collection was stress-free. Handling resulted in 
a small plasma CS increase, which was significant (see legend to 
figures for the results of ANOVA) at t = 15 and 30 min and re- 
turned to basal evel at 60 min. Intraperitoneal injection of acidi- 
fied saline or buffer (pH = 5) solution produced a similar pattern 
of changes in plasma CS levels as compared to that of the han- 
dled group of rats (Fig. 1A). The plasma CS values at 15 and 30 
min after injection were elevated approximately 4- to 5-fold as 
compared to controls or preinjection levels, but were not signifi- 
cantly higher than the corresponding handling-elevated values. In 
contrast, following IP administration f a buffer solution with 
pH = 3, the increases in CS were evidently more pronounced and 
longer lasting than the increments after either handling, saline- 
injection or buffer pH = 5 administration. A single-dose adminis- 
tration of CDP produced a marked, long-term increase (10- to 
15-fold) in plasma CS concentration. The CDP-induced increases 
at t = 15 and 30 min did not differ from the corresponding pH 3 
buffer-treated values but were significantly higher as compared to 
the values of the other groups of rats. 
Unlike after IP injection, plasma CS levels did not change 
over time following intragastrically applied acidified saline or 
buffer solution with pH= 3 (Fig. 1B). However, intragastric ad- 
ministration of 20 mg/kg CDP resulted in significant CS eleva- 
tions at t= 30, 60 and 120 min. The time courses of the CDP- 
induced plasma CS changes following the two methods of drug 
administration were compared using a two-way ANOVA with 
method of drug administration as between-subject factor and sam- 
piing time as repeated measures within-subject factor. In addition 
to significant main effects of method, F(1,10)=60.8, and sam- 
piing time, F(4,7)= 137, a significant method x time interaction 
effect was found, F(4,7)= 14.8. This indicates that the profile of 
CDP-induced changes in CS contents were different between the 
two methods of drug delivery. The CS values at t = 15, 30 and 
60 min after IP administered CDP were significantly higher as 
compared to the corresponding values following intragastrically 
applied CDP. These differences in CS levels were not due to dif- 
ferences in plasma CDP concentrations, since the time course of 
plasma CDP levels following intraperitoneal nd intragastric ad- 
ministration of 20 mg/kg CDP were grossly similar (Fig. 2). Al- 
though the increase in CDP levels over the sampling period tended 
to be somewhat higher in the IP dosed group as compared to the 
intragastrically treated group of animals, this difference only 
reached significance at t= 15 min after drug administration (see 
legend to Fig. 2 for results of ANOVA). 
Plasma NA and A concentrations did not vary significantly 
over the sampling period in any of the different treatment groups 
of rats. In all groups of rats plasma NA fluctuated within narrow 
limits around amean of 456---41 pg/ml. Circulating A fluctuated 
closely around a mean of 235 --- 22 pg/ml. 
Experiment 2 
As illustrated in Fig. 3, intragastric administration f the BDZ 
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FIG. 1. Time course of plasma corticosterone (CS) levels following 20 mg/kg chlordiazepoxide (CDP) 
and various vehicle solutions (acidified saline, buffer pH = 3 and buffer pH = 5) administered either by 
intraperitoneal injection (A) or by intragastric nfusion via an indwelling stomach catheter (B). Also il- 
lustrated are the CS levels of control rats left undisturbed in their home cages (A and B), and of handled 
rats (A). Data represent mean --- SEM from 6 animals per treatment-condition. Results of ANOVA on the 
data presented in A are as follows: F(treatment)(5,30)= 68.9, p<0.001, F(time)(4,27)= 125, p<0.001, 
F(treatment x time)(20,120)= 6.71, p<0.001. Results from ANOVA on data in B: F(treatment)(3,20) = 
73.7, p<0.001, F(time)(4,17) = 39.3, p<0.001, F(treatment × time)(12,57) = 2.77, p<0.01. *Significantly 
different from corresponding control value or from preinjection (t=0 min) value. "tSignificantly differ- 
ent from buffer pH = 3-treated group values at similar time points. 
inverse agonist DMCM (10 mg/kg) resulted in rapid, time-related 
increases in plasma CS, A and NA concentrations. Maximal CS 
levels (15-fold increase over baseline) were achieved between 30 
and 60 min after DMCM administration, whereafter they declined 
and returned at t= 180 min to basal values. Plasma A, which is 
released almost exclusively from the adrenal medullae, was ele- 
vated approximately 3.5- to 4-fold as compared to vehicle/saline 
controls or pretreatment values. The DMCM-induced increases in 
plasma A returned towards basal level by 60 min (Fig. 3B). 
Plasma NA, which is primarily released from sympathetic nerve 
endings, increased approximately 1.5-fold at 15 min following 
DMCM administration and returned to basal evel by 30 min (Fig. 
3B). The DMCM-induced plasma CS, A and NA elevations were 
completely blocked after pretreatment with the BDZ antagonist 
flumazenil (20 mg/kg). Flumazenil when administered alone, did 
not affect plasma CS and CA concentrations. 
Intragastric administration of CDP (20 mg/kg) resulted in a 
profile of CS elevations imilar to that observed in Experiment 1. 
Accordingly, the 20 mg/kg dose of CDP did not affect plasma 
NA and A concentrations. The CDP-evoked rise in CS differed 
from the DMCM-induced CS elevation both in magnitude (low- 
er) and temporal pattern (longer lasting). However, like the DMCM- 
induced response, the CDP-elicited rise in CS was completely 
antagonized following combined treatment with flumazenil (20 
mg/kg). 
Table 1 shows the dynamics of plasma BDZ receptor activity 
(expressed as CDP equivalents) following single-dose administra- 
tion of CDP, flumazenil and DMCM. All three BDZ ligands are 
rapidly absorbed after intragastric administration, reaching peak 
levels in about 15-30 min. Thereafter, BDZ activity declined rap- 
idly in the case of flumazenil and DMCM, but remained elevated 
in the case of CDP treatment. 
DISCUSSION 
The results demonstrate hat acute enteral (i.e., intragastric) or 
parenteral (i.e., intraperitoneal) administration of CDP to rats 
elicits a significant increase in plasma CS concentrations Without 
any significant effect on circulating levels of NA and A. Clearly, 
the nondrug-related stress associated with the intraperitoneal in- 
jection procedure (i.e., handling, visceral disturbance arising from 
unphysiological physicochemical properties of the drug solution) 
contributes ignificantly to the IP CDP-induced rise in CS. Simi- 
lar nondrug-related stress effects are absent when CDP is admin- 
istered via an intragastric annula, indicating that this method of 
drug administration can be used successfully to study the actions 
of drugs on neuroendocrine parameters in undisturbed freely be- 
having rats. It has previously been shown that handling and in- 
traperitoneal injection of saline results in an enhancement of 
plasma CS levels in rats (21,27). Furthermore, our CDP effects 
on plasma CS are in general agreement with several other studies 
(17, 20, 31) demonstrating elevation of CS triggered by acute in- 
traperitoneal or subcutaneous BDZ agonist administration i clud- 
ing CDP. Since the increases in basal CS concentration are only 
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FIG. 2. Time course of plasma CDP concentrations (as determined by 
benzodiazepine radioreceptor assay) following acute intraperitoneal (c osed 
symbols) or intragastric (open symbols) administration f 20 mg/kg CDP 
to unstressed rats. Data are expressed as mean ± SEM for groups of 6 an- 
imals. ANOVA revealed a tendency (p=0.06) for the treatment factor to 
be significant, F(1,10)=4.08, and a significant main effect of time, 
F(4,7) = 27.1. The interaction treatment x time was not significant. As- 
terisk indicates a significant difference between the two group values 
(Duncan's new multiple range test). 
seen with the use of medium to high, sedative, doses of CDP and 
not with low doses, it has been suggested that these effects are 
related to the behaviorally depressant action of CDP (18,31). The 
lack of significant increases in plasma NA and A contents follow- 
ing handling and intraperitoneal vehicle injection is most likely 
due to the timing of sample collection. In previous reports we 
have demonstrated that handling produced rapid but transient (re- 
turn to basal values within 15 min) elevations in NA and A (9). 
Accordingly, a rapid CDP-induced rise and fall in plasma CA 
concentration within 15 min may have been missed in this study. 
It has been established previously that BDZ agonists influence 
CS secretion through a central (i.e., brain) rather than peripheral 
(i.e., pituitary or adrenal gland) site of action (19,20). To date, 
the exact receptor mechanism (i.e., central-type or peripheral- 
type BDZ receptor) has not been elucidated. Results from the 
present study, however, show that coadministration of the cen- 
tral-type BDZ receptor antagonist flumazenil completely pre- 
vented the CDP-induced elevation of CS secretion. This is clear 
evidence that the effects of CDP upon the pituitary-adrenocortical 
axis in unstressed rats are mediated by central-type BDZ recep- 
tors. Since pituitary-adrenocortical output is regulated by a num- 
ber of CNS pathways (1,12) which are all subserved by BDZ 
receptors (36), the specific loci of this CDP-mediated action re- 
main unknown. 
Intragastric administration of the BDZ inverse agonist DMCM 
produces a marked rise in rat CS levels. But, in contrast o CDP, 
DMCM causes ubstantial increases in plasma NA and A concen- 
trations, indicating sympatho-adrenal activation. The greater adren- 
aline than noradrenaline r lease suggests that the adrenomedullary 
component of the sympatho-adrenal system is activated more by 
DMCM than the neurosympathetic branch. Given the anxiogenic 
properties of DMCM, this result reinforces the view (7,9) that 
plasma A concentration is a hormonal index of emotional stress, 
whereas plasma NA contents is more related to physical activity. 
More or less similar stress-like ffects of BDZ inverse agonists 
have previously been reported (6, 25, 26, 29, 32). 
The present finding that flumazenil effectively blocks the 
DMCM-elicited CS and CA response, is consistent with another 
study (25) showing that the anxiogenic effects of inverse agonist 
13-carbolines are mediated through central-type BDZ receptors. 
TABLE 1 
DYNAMICS OF PLASMA BENZODIAZEPINE RECEPTOR BINDING ACTIVITY FOLLOWING INTRAGASTRIC 
ADMINISTRATION OF CDP, FLUMAZENIL AND DMCM 
Time After Drug Administration (min) 
0 15 30 60 120 180 
CDP 4.8 ± 0.8 27.9 -+ 2.8* 30.1 - 3.6* 31.3 - 3.6* 31.3 ± 5.2* 26.7 - 4.8* 
(20 mg/kg) 
Flumazenil 8.7 -+ 23~7 323.6 -+ 145.5"t 341.1 -+ 127.7"t 126.2 ± 55.2"t 31.8 -+ 14.0" 2.9 -+ 9.8t$ 
(20 mg/kg) 
DMCM 2.4 ± 1.7 285.7 -+ 46.3"t 244.1 -+ 77.5"t 126.0 -+ 41.6"t 46.1 _+ 11.1" 57.8 -+ 13.8" 
(10 mg/kg) 
Values (mean +_ SEM) are expressed as CDP equivalents (l~mol/l) of benzodiazepine plasma levels as determined 
by radioreeeptor assay, n = 6 for each drug-treatment group. 
Two-way ANOVA on the values revealed significant effects of the main factor time, F(5,11)= 13.5, p<0.00l, and 
a significant treatment x time interaction effect, F(10,24)=3.87, p<0.01. Results of subsequent analyses are indi- 
cated by the following symbols: *p<0.05 as compared to the basal, time 0, value of the respective group, tp<0.05 
as compared to corresponding CDP group value. ~p<0.05 as compared to corresponding flurnazenil group value. 
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FIG. 3. Time course of plasma corticosterone (A), noradrenaline and adrenaline (B) levels after intragastric administration of CDP (20 mg/kg; n = 
6), DMCM (10 mg/kg; n = 11) or acidified saline (2 ml/kg) combined with either fiumazenil (20 mg/kg) or the flumazenil vehicle (2 ml/kg). Data 
represent mean -+ SEM. For the corticosterone and adrenaline data, three-way ANOVA revealed in addition to significant main and two-way inter- 
action effects of drug condition, flumazenil treatment and sampling time, a significant hree-way interaction [CS: F(10,34)= 10.4, p<0.001, A: 
F(10,34) = 2.45, p = 0.025]. ANOVA on the NA data only disclosed a significant main effect of time, F(5,16) = 3.27, p<0.05. *Significantly dif- 
ferent from corresponding vehicle/saline- and flumazenil/dmg-treated group values, tSignificantly different from corresponding vehicle/CDP group 
value. 
According to the present results, it seems that occupation of cen- 
tral BDZ receptors either by agonists or inverse agonists produces 
qualitatively similar effects on the pituitary-adrenocortical axis, 
despite their opposite biochemical/electrophysiological intrinsic 
actions at the GABA-gated chloride ionophore. Thus it is clear 
that measurement of basal CS concentrations alone cannot be used 
as a hormonal predictor of agonist- or inverse agonist-like actions 
at the level of the BDZ/GABA receptor chloride ionophore corn- 
plex. Determination of plasma NA and A levels may prove to be 
better hormonal indices in this respect. 
In summary, this study shows that the CNS pathways regulat- 
ing pituitary-adrenocortical nd sympatho-adrenal output are func- 
tionally subserved by central-type BDZ receptors. Whether these 
receptors have a physiological role in the absence of an exoge- 
nous ligand is still a matter of considerable speculation. Final 
proof awaits the discovery of its putative endogenous ligand(s). 
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